Davide Malacarne
Overview
Explore the profile of Davide Malacarne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vimercati L, Cavone D, Negrisolo O, Pentimone F, De Maria L, Caputi A, et al.
Med Lav
. 2023 Oct;
114(5):e2023038.
PMID: 37878258
The study describes the 466 cases of malignant mesotheliomas (MM) collected by the National Mesothelioma Register (ReNaM) in Italy in the period 1993-2018 relating to subjects with exclusive asbestos exposure...
2.
Vimercati L, Cavone D, De Maria L, Caputi A, Pentimone F, Sponselli S, et al.
Med Lav
. 2023 Jun;
114(3):e2023025.
PMID: 37309879
Background: An increased risk of mesothelioma has been reported in various countries for construction workers. The Italian National Mesothelioma Registry, from 1993 to 2018, reported exposure exclusively in the construction...
3.
Binazzi A, di Marzio D, Verardo M, Migliore E, Benfatto L, Malacarne D, et al.
Int J Environ Res Public Health
. 2022 Jan;
19(1).
PMID: 35010496
Notwithstanding the ban in 1992, asbestos exposure for workers in the construction sector in Italy remains a concern. The purpose of this study is to describe the characteristics of malignant...
4.
Castagnola P, Gandolfo S, Malacarne D, Aiello C, Marino R, Zoppoli G, et al.
PLoS One
. 2017 Sep;
12(9):e0184425.
PMID: 28877236
The aim of this study was to investigate the relationship between tobacco smoke habit, patient age, DNA aneuploidy and genomic DNA copy number aberrations (CNAs) in oral potentially malignant disorder...
5.
Castagnola P, Zoppoli G, Gandolfo S, Monticone M, Malacarne D, Cirmena G, et al.
PLoS One
. 2015 Nov;
10(11):e0142294.
PMID: 26540282
Oral potentially malignant disorders (OPMDs) characterized by the presence of dysplasia and DNA copy number aberrations (CNAs), may reflect chromosomal instability (CIN) and predispose to oral squamous cell carcinoma (OSCC)....
6.
Giaretti W, Monteghirfo S, Pentenero M, Gandolfo S, Malacarne D, Castagnola P
Cancer Epidemiol Biomarkers Prev
. 2013 May;
22(6):1133-41.
PMID: 23629518
Background: Chromosomal instability and aneuploidy may represent biomarkers of oral exposure to damaging agents and early signs of clinical disease according to the theory of "oral field cancerization." Methods: The...
7.
Castagnola P, Malacarne D, Scaruffi P, Maffei M, Donadini A, Di Nallo E, et al.
BMC Cancer
. 2011 Oct;
11:445.
PMID: 21995418
Background: The mucosae of the oral cavity are different at the histological level but appear all equally exposed to common genotoxic agents. As a result of this exposure, changes in...
8.
Pentenero M, Giaretti W, Navone R, Rostan I, Gassino L, Broccoletti R, et al.
J Oral Pathol Med
. 2011 Jan;
40(3):214-7.
PMID: 21198867
Purpose: To test the hypothesis that cigarette smokers develop oral potentially malignant disorders or carcinomas in preferential anatomical subsites. Methods: The association of smoking habit with the presence of oral...
9.
Donadini A, Maffei M, Cavallero A, Pentenero M, Malacarne D, Di Nallo E, et al.
Cell Oncol
. 2010 May;
32(5-6):373-83.
PMID: 20448331
Oral potentially malignant lesions (OPMLs) with dysplasia and aneuploidy are thought to have a high risk of progression into oral squamous cell carcinomas (OSCCs). Non-dysplastic "oral distant fields" (ODFs), characterized...
10.
Pentenero M, Giaretti W, Navone R, Demurtas A, Rostan I, Bertolusso G, et al.
Oral Oncol
. 2009 May;
45(10):887-90.
PMID: 19457703
To date there are still no reliable biomarkers for oral potentially malignant disorders (PMDs) to predict the risk of progression to squamous cell carcinoma (SCC). Within a prospective clinical trial...